Cargando…
Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PTCy) offers universal donor availability and can potentially cure relapsed or primary refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). However, a conditioning regimen intensity...
Autor principal: | Patel, Dilan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396776/ https://www.ncbi.nlm.nih.gov/pubmed/30834047 http://dx.doi.org/10.14740/wjon1164 |
Ejemplares similares
-
Biomaterials for Testicular Bioengineering: How far have we come and where do we have to go?
por: Horvath-Pereira, Bianca de Oliveira, et al.
Publicado: (2023) -
Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go
por: Gajjela, Harini, et al.
Publicado: (2021) -
Managing sarcoma: where have we come from and where are we going?
por: Bleloch, Jenna S., et al.
Publicado: (2017) -
Paediatric Surgery on the African Continent: How Far Have We Come; How Far Can We Go?
por: Numanoglu, Alp
Publicado: (2023) -
Antibiotic Discovery: Where Have We Come from, Where Do We Go?
por: Ribeiro da Cunha, Bernardo, et al.
Publicado: (2019)